Intellia reported $7.2 million in third-quarter collaboration revenue and a net loss of $127.5 million. The firm is continuing to advance launch preparations for lonvo-z in hereditary angioedema ahead of its March 2027 US regulatory decision.
Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.
Intellia's pipeline is largely in the early stages of development and years away from potentially receiving approval.
Metric | NTLA | MRNA | CRSP |
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.61 | 14.70 | 2.69 |
Price/Sales | 27.42 | 39.13 | 188.63 |
Price/Cash Flow | — | — | — |
Metric | NTLA | MRNA | CRSP |
|---|---|---|---|
Quick Ratio | 6.00 | 3.34 | 16.12 |
Current Ratio | 6.31 | 3.62 | 16.21 |
Interest Coverage | — | −49.00 | — |
Metric | NTLA | MRNA | CRSP |
|---|---|---|---|
Return on Assets (Normalized) | −40.65% | −20.21% | −15.62% |
Return on Equity (Normalized) | −51.53% | −31.30% | −21.49% |
Return on Invested Capital (Normalized) | −46.90% | −27.15% | −16.45% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Yg#l&!# | LOCK|RmZK! | $139B | |||
| Moderna Inc MRNA | LOCK|HHJCJ?& | LOCK|sd$ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Z!Y@^T | LOCK|<y$>? | $99B | |||
| argenx SE ADR ARGX | LOCK|v$^C>@ | LOCK|?@ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|DwF?Pq | LOCK|n# | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%<<FBKS | LOCK|v^Z$ | $31B | |||
| Incyte Corp INCY | LOCK|<rr!dR | LOCK|?j | $25B | |||
| BioNTech SE ADR BNTX | LOCK|qvY?z< | LOCK|<$$ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|W$@h#< | LOCK|?#%dX | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|yyk^#DW | LOCK|?c& | $16B |
United States